FibroBiologics (NASDAQ:FBLG) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research note published on Tuesday,Benzinga reports. The firm currently has a $16.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of FibroBiologics in a research report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Stock Performance

Shares of FibroBiologics stock opened at $0.75 on Tuesday. The company has a market cap of $28.82 million, a P/E ratio of -3.59 and a beta of -0.80. FibroBiologics has a one year low of $0.70 and a one year high of $7.04. The firm has a fifty day moving average of $0.94 and a two-hundred day moving average of $1.37.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). As a group, equities analysts predict that FibroBiologics will post -0.53 earnings per share for the current year.

Hedge Funds Weigh In On FibroBiologics

A number of large investors have recently made changes to their positions in FBLG. Raymond James Financial Inc. purchased a new position in shares of FibroBiologics in the 4th quarter valued at about $37,000. Intech Investment Management LLC purchased a new position in shares of FibroBiologics in the 4th quarter valued at about $25,000. Virtu Financial LLC purchased a new position in shares of FibroBiologics in the 4th quarter valued at about $30,000. O Shaughnessy Asset Management LLC purchased a new position in shares of FibroBiologics in the 4th quarter valued at about $81,000. Finally, Cerity Partners LLC increased its holdings in shares of FibroBiologics by 49.9% in the 4th quarter. Cerity Partners LLC now owns 78,101 shares of the company’s stock valued at $156,000 after purchasing an additional 26,001 shares in the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.